Intellia Therapeutics' Shares Fall After Q2 Net Loss Narrows, Revenue Increases

MT Newswires Live08-07

Intellia Therapeutics' (NTLA) shares were down 1.3% in recent Thursday trading after the company reported a Q2 net loss of $0.98 per diluted share, narrower than its loss of $1.52 a year earlier.

Analysts polled by FactSet expected a loss of $1.02 per share.

Collaboration revenue for the quarter ended June 30 was $14.2 million, compared with $7.0 million a year earlier.

Analysts surveyed by FactSet expected $11.9 million.

The company said it had cash, cash equivalents, and marketable securities of $630.5 million as of June 30, which is expected to fund operations into H1 2027.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法